Liposomal oncolytic adenovirus as a neoadjuvant therapy for triple-negative breast cancer

Liposomal oncolytic adenovirus as a neoadjuvant therapy for triple-negative breast cancer

Abstract Breast cancer remains one of the leading causes of cancer-related death, with triple-negative breast cancer (TNBC) accounting for 15–20% of cases. TNBC, characterized by the absence of ER, PR, and HER2 protein, is an aggressive form of breast cancer that is unresponsive to hormonal therapie...

Full description

Saved in:
Bibliographic Details
Main Authors: Jaimin R. Shah, Tao Dong, Abraham T. Phung, Sohini Khan, Omonigho Aisagbonhi, Sarah L. Blair, Michael Bouvet, William C. Trogler, Andrew C. Kummel
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Triple-negative breast cancer
Neoadjuvant therapy
Oncolytic adenovirus
Coxsackievirus and adenovirus receptor
Liposomes
Metastasis
Online Access:https://doi.org/10.1038/s41598-025-00211-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-00211-2

Similar Items